FibroBiologics reports preclinical success of FSdC spheroids in rabbit disc degeneration model
FibroBiologics presented preclinical results at the North American Spine Society 2026 Annual Meeting. The study compared three allogeneic fibroblast‑based treatments in a 12‑week rabbit model of intervertebral disc degeneration. The fibroblast spheroid‑derived chondrocyte (FSdC) spheroids achieved the highest normalized percent disc height index, preserving disc height better than the other approaches. The data suggest the platform may restore lost disc cells and matrix.
Why it matters
The company’s press release highlights a potential disease‑modifying therapy for degenerative disc disease, which could expand its pipeline and attract development partners. Investors may view the results as a de‑risking milestone for FibroBiologics' cell‑therapy platform.
Key facts
- 1The presentation was delivered by Nikolay Bazhanov, M.D., Ph.D., on Thursday, October 15, 2026 at the NASS Annual Meeting in San Antonio. prnewswire.com
- 2The preclinical study used a rabbit model of intervertebral disc degeneration over a 12‑week period. prnewswire.com
- 3Three fibroblast‑based approaches were tested: conventional 2D fibroblasts, 3D fibroblast spheroids, and fibroblast spheroid‑derived chondrocytes (FSdC). prnewswire.com
- 4All three treated groups showed higher disc heights than vehicle controls, with statistical significance for the 2D fibroblasts (p<0.05), the 3D spheroids (p<0.05), and the FSdC spheroids (p<0.01). prnewswire.com
- 5At the end of 12 weeks, the FSdC spheroid group recorded a percent disc height index of 80.7%, compared with 71.8% in the control group (p<0.05). prnewswire.com
- 6FibroBiologics holds more than 270 U.S. and international patents and pending patents across multiple therapeutic areas. prnewswire.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.